Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
depatuxizumab mafodotin
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) developed for the treatment of cancer, particularly glioblastoma and other solid tumors. It consists of a humanized IgG1 monoclonal antibody (depatuxizumab) targeting the epidermal growth factor receptor (EGFR), including tumor-specific EGFR epitopes and mutant forms such as EGFRvIII, conjugated via a stable maleimidocaproyl linker to the cytotoxic agent monomethyl auristatin F (MMAF), a tubulin inhibitor. Upon binding to EGFR-expressing tumor cells, the ADC is internalized and releases MMAF intracellularly, leading to inhibition of tubulin polymerization, mitotic arrest, apoptosis induction, and subsequent cell death. The drug was granted orphan drug status for glioblastoma but its development was discontinued after late-stage clinical trial failures[1][3][5][6].
- Brand names
- Depatux-M
- Other names
- depatuxizumab mafodotinABT-414ABT414ABT 414Depatux-M
02
Targets
EGFR (Epidermal growth factor receptor)EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on depatuxizumab mafodotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on depatuxizumab mafodotin.